Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspire Bariatrics Inc.

Fighting morbid obesity with stomach aspiration

This article was originally published in Start Up

Executive Summary

An ideal minimally invasive bariatric technology should be safe, easily implantable, suitable as a permanent therapy, and allow patients to eat a normal diet. Aspire Bariatrics Inc. thinks its solution fits the bill. With the AspireAssist Aspiration Therapy System, patients have control over their weight loss as they are able, about 20 minutes after a meal, to drain a portion of their stomach contents through an endoscopically implanted tube, thus reducing the number of calories absorbed by the body.

You may also be interested in...



Obesity Devices: The Next Wave

Several emerging medtechs are developing products and procedures that are less invasive, less expensive, easier to deliver, and more easily reversible than bariatric surgery. With support from investors and the FDA, these firms are poised to reap big rewards in the massive, undermet obesity market.

Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For Solutions

Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.

Vibrynt Inc.

Vibrynt Inc.’s adjustable VIBRYNT PREVAIL Implant System is a saline-filled, silicone bladder designed to limit the stomach's ability to expand beyond the size of a small tube, and thus limit food consumption and calorie intake. The permanent implant is placed laparoscopically on the top of but still outside the stomach, and is designed to occupy the space that the stomach would normally expand to as a meal is eaten. Unlike the currently available surgical options, with the Vibrynt system there is no altering of the gastrointestinal anatomy and there are no restrictions on the types of healthy foods patients can eat.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel